Post Nephrectomy

MK6482-022: Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482Plus Pembrolizumab (MK-3475Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCCPost Nephrectomy (MK-6482-022)

Phase: 3
Study Product: Belzutifan (placebo-controlled) + Pembro adjuvant tx of intermediate-high/high risk or M1 NED ccRCC 
Estimated Study Completion Date: January 25, 2030 Identifier: NCT05239728

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember to talk to your healthcare providers first before making decisions about your plan of care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study. To learn more about our trials, call Jennifer at (843) 449-1010 ext. 316 or email us by filling out the form below.